Profilo
Michael J.
Marquard was Chief Executive Officer and a Director of PDI, Inc. from May 2006 to June 20, 2008.
Prior to joining PDI, he had served as Vice President of Mylan Laboratories, Inc. and President of Mylan Bertek Pharmaceuticals, Inc. since July 2004.
Previously, Mr. Marquard served as Senior Vice President of U.S.
Sales for Wyeth since 1996 and served as a Member of the U.S.
Management Team and the Pharmaceutical Business Unit's Global Leadership Team.
From 1973 to 1995, he held a variety of positions at American Cyanamid Company, including Vice President and General Manager of Lederle Pharmaceuticals, Vice President and General Manager of Lederle Oncology and Vice President of Sales for Lederle Laboratories.
Mr. Marquard received an MBA from the University of Indianapolis and a BS from Youngstown State University.
Precedenti posizioni note di Michael J. Marquard
| Società | Posizione | Fine |
|---|---|---|
| INTERPACE BIOSCIENCES, INC. | Presidente | 20/06/2008 |
Mylan Laboratories, Inc.
 Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INTERPACE BIOSCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Health Technology |
- Borsa valori
- Insiders
- Michael J. Marquard
